Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-dose baloxavir marboxil 2% granules in pediatric influenza (≤20 kg)
jRCT2080223755Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of baloxavir marboxil in influenza, sponsored by Shionogi & Co., Ltd. Primary endpoints: Safety and tolerability of single-dose baloxavir marboxil 2% granules, Pharmacokinetics of baloxavir marboxil and its active metabolite and 1 more. Started Dec 2017; status: completed.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on jRCT2080223755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223755.